The round was backed by the two existing investors, Bionova Capital and Caixa Capital, as well as two new investors, Kiilto Ventures from Finland and a Portuguese business angel.
Portuguese startup Delox raised €750,000 in a new investment round, bringing the total capital raised to over €1.3 million. The round was backed by the two existing investors, Bionova Capital and Caixa Capital, as well as two new investors, Kiilto Ventures from Finland and a Portuguese business angel.
“We are launching this new product to address a market need for an effective and cost-efficient system for bio-decontamination of laboratory equipment. We have conducted several pilot studies in the US and Europe, and the effectiveness and fit of our product to the market needs has been confirmed. This new funding will also allow us to certify this product and develop additional products for customers in the hospital and pharmaceutical industry,” said Fadhil Musa, CEO of Delox, in a statement.
Bionova Capital made the initial pre-seed investment that allowed Delox – a spin-off from the Faculty of Science at the University of Lisbon that has developed a new bio-decontamination system capable of eliminating 99.9999% of all microorganisms from the surfaces of laboratory equipment and workspaces, including bacteria and viruses – to establish itself, in 2018.
“When we first met with the founders, they were looking for the first funding to be able to establish the company. Since then, we have worked closely with them to help them bring their innovative technology to market. We are therefore delighted to witness the launch of this innovative product into the global marketplace,” confesses Peter Villax, chairman of Bionova Capital.
“Delox is another good example of our role in creating healthcare startups across Europe. Bionova Capital helped developing this complex product, which combines chemistry with engineering, as well as recruiting the company’s chairman and advisory board,” adds Ricardo Perdigão Henriques, CEO of Bionova Capital.